Vesugen
Vesugen
Peptide bioregulator researched for vascular wall and cardiovascular support.
Key takeaways
- Synthetic vascular-targeted tripeptide (Lys-Glu-Asp) from the Khavinson bioregulator program.
- Evidence is cell-culture and animal atherosclerosis work, almost all single-group; no human trials.
- Plotter values are estimates modeled on similar short peptides, not measured human PK.
- Reported 10–20 day courses are anecdotal; no established human dosing exists.
Reported dosing protocols
Protocols reported in research literature and clinic/community use — informational context, not a dosing recommendation.
| Use case | Dose | Route | Frequency | Duration |
|---|---|---|---|---|
| Vascular support (community) | 1–2 mg | SubQ; oral capsules also sold | Once daily | 10–20 days, repeated 2–3× yearly |
Pharmacokinetic summary
- Model tier
- Simple (t½ + F, Tmax estimated)
- Half-life
- 4.1 hours
- Bioavailability
- 40%
- Typical dose
- 0.5–2 mg
Frequently asked questions
Can Vesugen prevent atherosclerosis?
No human evidence supports that. Animal and cell studies from the originating group describe endothelial effects, but no randomized trial has tested Vesugen for any cardiovascular outcome.
Is Vesugen a blood thinner?
No. It's a short peptide claimed to regulate endothelial gene expression; it has no established anticoagulant or antiplatelet action, and it isn't a substitute for prescribed cardiovascular medication.
Has Vesugen been replicated independently?
Not meaningfully. The indexed literature traces to the Khavinson institute and affiliated journals, with essentially no confirmation from independent labs.
References
- Estimated (bioregulator) — Vascular-wall peptide bioregulator.
- Adv Gerontol 2016 — vasoprotective peptide KED in atherosclerosis and restenosis — Single-group review of KED (Vesugen) vascular mechanisms.
- Mol Biol Rep 2020 — short peptides modulate gene expression in aging stem-cell cultures — In-vitro study of KED (with AED and KE) on IGF1, TERT, and other aging-related genes.
Related compounds
Comments
Loading comments…